These findings enhanced our knowledge of the role of TGF-β1 in AF, and suggested that the C-509T polymorphism could be a functional genetic target for developing new treatment strategies and guide the physicians for catheter ablation as a useful marker. This evidence concerns the gene TGFB1 and atrial fibrillation.